Ipilimumab
This immunotherapy drug is a checkpoint inhibitor that blocks CTLA-4, a protein on immune T-cells that normally acts as a brake on immune activity. By releasing this brake, it allows the immune system to mount a more powerful attack against cancer cells. It is used to treat advanced melanoma, kidney cancer, lung cancer, and other malignancies, often in combination with another checkpoint inhibitor.
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This immunotherapy drug is a checkpoint inhibitor that blocks CTLA-4, a protein on immune T-cells that normally acts as a brake on immune activity. By releasing this brake, it allows the immune system to mount a more powerful attack against cancer cells. It is used to treat advanced melanoma, kidney cancer, lung cancer, and other malignancies, often in combination with another checkpoint inhibitor.
Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Key pharmacokinetic parameters for Ipilimumab: Half-life: 14.7 days.
Yes, Ipilimumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1789844. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ipilimumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ipilimumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ipilimumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ipilimumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ipilimumab"></drugfyi-drug>